Part 8/8:
The pharmaceutical and biopharmaceutical industries find themselves at a critical juncture, navigating complex trade and policy landscapes. While tariffs have been somewhat manageable, looming changes in drug pricing regulations pose significant risks and opportunities. As the sector awaits clearer guidance and concrete policy actions, companies that proactively adapt their manufacturing strategies and strategic planning will be better positioned to weather these changes, ensuring continued growth and innovation in a highly dynamic environment.